evipedia.ai
← Back

Female HRT for Health & Longevity

Evidence Review created on 09/14/2026 using AI4L / Opus 5

Also known as: Menopausal Hormone Therapy, MHT, Hormone Replacement Therapy, HRT, Postmenopausal Hormone Therapy, Menopausal Hormone Treatment, Estrogen Therapy, Estrogen-Progestogen Therapy, Estradiol, Estriol, Conjugated Equine Estrogens, Micronized Progesterone, Medroxyprogesterone Acetate, Dydrogesterone, Norethisterone Acetate, Levonorgestrel, Tibolone, Premarin, Prempro, Estrace, Climara, Vivelle-Dot, Divigel, EstroGel, Prometrium, Utrogestan, Duavee, Mirena

Motivation

Female HRT (hormone replacement therapy) is the use of estrogen — usually together with progesterone or a related hormone when the uterus is still present, and sometimes with a small dose of testosterone — to replace what the ovaries stop producing at menopause. It is given as tablets, transdermal patches, gels, sprays, or vaginal preparations.

Estrogen acts on bone and on blood vessels, so its loss is felt across several systems at once. Hormone therapy was widely prescribed through the 1990s, then use collapsed after a large government-funded trial was stopped early. Later work in women closer to their final menstrual period painted a different picture, and prescribing has been rising again.

This review examines what the evidence shows about female HRT and long-term health: which outcomes improve, which worsen, how the route of administration and the choice of hormone change that balance, at what point in life the picture shifts, and how solid the underlying studies actually are.

Benefits - Risks - Protocol - Conclusion

High-level overviews of female hormone therapy from clinicians and longevity-focused publications that treat the topic in depth.

FoundMyFitness (Rhonda Patrick) addresses hormone therapy only inside broader question-and-answer episodes rather than in a dedicated treatment of the topic, so no item from that platform met the depth bar set above and none is listed.

Grokipedia

  • Hormone replacement therapy

    A long, heavily referenced entry covering formulations, routes, the trial history, and the regimen-specific risk profile, with unusually direct treatment of the disputes over breast cancer risk.

Examine

No dedicated Examine article exists for female HRT. The site’s only direct coverage is a single frequently-asked-question entry on hormone therapy risks, which is an FAQ page rather than a primary, dedicated page for the intervention.

Because female HRT is a prescription therapy, this absence is expected: Examine.com covers dietary supplements and nutrition interventions and does not typically produce dedicated pages for prescription medications.

ConsumerLab

No dedicated ConsumerLab article exists for female HRT.

Because female HRT is a prescription therapy, this absence is expected: ConsumerLab independently tests dietary supplements and over-the-counter products and does not typically cover prescription medications.

Systematic Reviews

The systematic reviews and meta-analyses below cover the claimed long-term effects of female HRT and its principal risks — breast cancer and dementia — as well as its net effect on death from any cause.

Mechanism of Action

Estradiol, the dominant circulating estrogen before menopause, acts through two nuclear estrogen receptors (ERα and ERβ) and a membrane receptor, GPER. Bound receptors change gene transcription in bone, blood vessel lining, brain, liver, skin, and the genital and urinary tract, which is why ovarian failure affects many tissues at once. In bone, estradiol restrains osteoclasts (the cells that dissolve bone), slowing the accelerated loss of early menopause. In arteries it increases nitric oxide (a molecule that relaxes vessel walls) and improves endothelial function. In the hypothalamic thermoregulatory centre it dampens the KNDy neurons (the cells that trigger flushing).

A progestogen (the drug class containing progesterone and its synthetic relatives) is added for one reason: estrogen alone drives proliferation of the endometrium (the lining of the uterus), and a progestogen opposes it. The two are given together for a protective, not additive, effect. Micronized progesterone also binds GABA-A receptors (the brain’s calming switch), producing sedation; synthetic progestins instead carry androgenic or glucocorticoid activity.

Co-administration matters pharmacologically. Both hormones are cleared largely by CYP3A4 (a liver enzyme metabolising many drugs), so inducers and inhibitors shift both at once. Oral estradiol undergoes hepatic first-pass metabolism, raising clotting factors, sex hormone binding globulin (the protein carrying sex hormones), and triglycerides; transdermal estradiol (absorbed through the skin) bypasses this. Estradiol’s oral half-life is roughly 12–14 hours, oral micronized progesterone’s about 5 hours.

A competing account holds estrogen is vasculoprotective only in healthy arteries and destabilises established plaque, the core of the timing dispute.

Historical Context & Evolution

Conjugated equine estrogens (estrogens extracted from the urine of pregnant mares) were approved in North America in 1942 for hot flushes and night sweats. Use expanded after 1966, when a widely read popular book framed menopause as a deficiency disease to be corrected indefinitely. In the mid-1970s case-control studies linked unopposed estrogen to a sharp rise in endometrial cancer, a finding randomised evidence has since confirmed at every dose studied. The response was not withdrawal but the addition of a progestogen for women with a uterus.

Through the 1980s and 1990s large observational cohorts reported substantially lower mortality among users, and therapy was increasingly prescribed for prevention rather than symptoms. Two randomised trials then tested that claim. A secondary-prevention trial in women with existing heart disease, funded by the manufacturer of the study drug, found no benefit and early excess events. The large publicly funded primary-prevention trial stopped its estrogen-progestogen arm in 2002 after crossing a boundary for breast cancer, with excess stroke and clots; prescribing fell sharply within two years.

The findings themselves have not been overturned, but their scope has narrowed. The trial’s mean enrolment age was over 60, and later age-stratified analyses of the same data reported a different coronary signal in women aged 50–59, a pattern motivating the timing hypothesis and two dedicated trials. Long-term follow-up found no effect on death from any cause. In late 2025 the United States regulator moved to strip the boxed warning from systemic hormone products, a reversal still contested.

Expected Benefits

High 🟩 🟩 🟩

Relief of Vasomotor Symptoms

Vasomotor symptoms (hot flushes and night sweats) are the reason most women start therapy, and the effect is the largest and most reproducible in the field. Estrogen acts on hypothalamic temperature-regulating neurons to restore normal temperature control. The evidence is a Cochrane meta-analysis of 24 double-blind placebo-controlled trials in 3,329 women, covering both estrogen-only and estrogen-progestogen regimens; both work. The placebo response in these trials is itself large, around 58%, which is why uncontrolled reports overstate the effect.

Magnitude: 75% reduction in weekly hot-flush frequency relative to placebo (95% CI 64.3 to 82.3 — a confidence interval is the range within which the true value is expected to lie), with severity also reduced (OR 0.13, 95% CI 0.07 to 0.23; an odds ratio compares the odds of an outcome between two groups), per the Cochrane meta-analysis of oral therapy versus placebo.

Prevention of Osteoporotic Fracture

Estrogen withdrawal drives the fastest bone loss of a woman’s life in the five to seven years after the final period; replacing it restrains osteoclast activity and halts that loss. Fracture reduction appeared in both arms of the large randomised programme — estrogen-progestogen and estrogen-only — and in an unselected population rather than a high-risk one. Bone mineral density (the mineral packed into bone, measured by scan) rises alongside it. The effect reverses within a few years of stopping.

Magnitude: total fractures reduced 24% with estrogen plus progestogen (HR 0.76, 95% CI 0.69 to 0.83 — a hazard ratio compares the rate of an event between groups over time), 8.6% versus 11.1% over 5.6 years, with total hip bone density up 3.7% versus 0.14%, per the Women’s Health Initiative fracture analysis; the Cochrane review gives RR 0.78 for combined and RR 0.73 for estrogen-only therapy (a risk ratio compares the probability of an event between groups).

Relief of Genitourinary Syndrome of Menopause

Genitourinary syndrome of menopause is the cluster of vaginal dryness, dyspareunia (painful intercourse), urinary urgency and frequency, and recurrent urinary tract infections that follows estrogen loss from the vulvovaginal and lower urinary tract tissue. Unlike hot flushes it does not remit with time and worsens without treatment. Low-dose vaginal estrogen — estradiol or estriol as cream, tablet, or ring — restores epithelial thickness, blood flow, and the acidic vaginal environment. The systematic review base covers 44 randomised and prospective comparative studies of all marketed preparations.

Magnitude: vaginal estrogen improves dryness, painful intercourse, urgency, frequency, and both stress and urge incontinence versus placebo, and lowers urinary tract infection rates, with the benefit holding across every marketed preparation; the pooling systematic review reports direction and consistency but no single pooled outcome figure across the heterogeneous symptom scales used.

Lower Incidence of Type 2 Diabetes

Estrogen improves insulin sensitivity and reduces visceral fat accumulation. The effect on diagnosed diabetes appeared in the estrogen-progestogen arm of the large randomised programme and is supported by pooled randomised data across regimens in the umbrella review. It is not a licensed indication anywhere, and the absolute reduction is modest in women without metabolic risk factors; for a metabolically vulnerable woman in her early fifties it is more consequential.

Magnitude: treated diabetes fell from 4.2% to 3.5% over 5.6 years with estrogen plus progestogen (HR 0.79, 95% CI 0.67 to 0.93), alongside a measurable fall in insulin resistance, per the Women’s Health Initiative diabetes analysis; pooled randomised data across regimens are directionally consistent in the umbrella review.

Improved Sleep Quality in Women With Night Sweats

Broken sleep is reported by 40–60% of menopausal women and is itself a risk factor for cardiometabolic disease. Hormone therapy improves self-reported sleep quality, but the meta-analysis is explicit that the effect is confined to women who have vasomotor symptoms at baseline — in women without them, no difference was detectable. The mechanism is therefore largely, though perhaps not entirely, removal of night-time flushing. Oral micronized progesterone adds a separate sedative effect through GABA-A receptors that the pooled estrogen data do not isolate.

Magnitude: standardised mean difference −0.54 (95% CI −0.91 to −0.18 — a standardised mean difference expresses the size of a change in units of the spread of the measurements, so results from different scales can be pooled) in sleep quality among women with vasomotor symptoms at baseline, from seven trials enrolling 15,468 women, with no detectable difference in women without such symptoms, per the meta-analysis of hormone therapy and sleep quality.

Improved Sexual Function With Added Testosterone

Testosterone is the component of female hormone therapy most often omitted and is the one with the cleanest randomised evidence for sexual outcomes. The meta-analysis covers 36 blinded randomised trials in 8,480 women, most of them postmenopausal, and includes unpublished regulatory submissions. Benefit spans desire, arousal, orgasm, pleasure, and distress. Route matters: oral testosterone worsened the lipid profile while transdermal application did not. Acne and hair growth were more common; no serious adverse events were recorded, and long-term safety data remain thin.

Magnitude: satisfying sexual event frequency increased by 0.85 events per month (95% CI 0.52 to 1.18) and sexual desire by a standardised mean difference of 0.36 (95% CI 0.22 to 0.50) versus placebo or estrogen comparator, per the meta-analysis of testosterone in women.

Medium 🟩 🟩

Prevention of Depressive Symptoms During the Menopause Transition

The perimenopause carries a two-to-four-fold rise in clinically significant depressive symptoms, attributed to the volatility rather than the absolute level of estradiol. A single randomised placebo-controlled trial tested whether transdermal estradiol with intermittent oral micronized progesterone could prevent that onset in women who were not depressed at entry, and it did. Benefit was concentrated in the early menopause transition and in women with recent stressful life events; it was absent in women already postmenopausal. This is prevention of onset, not treatment of established major depression.

Magnitude: 17.3% of treated women versus 32.3% on placebo scored 16 or above at least once on the CES-D scale (Center for Epidemiologic Studies Depression Scale, a validated self-report depression questionnaire) over 12 months, an odds ratio of 2.5 for placebo versus treatment (95% CI 1.1 to 5.7), per the randomised prevention trial of transdermal estradiol and micronized progesterone.

Reduced Joint Pain and Stiffness

Musculoskeletal pain is among the most commonly reported menopausal complaints and is rarely attributed to hormone loss. Estrogen receptors in cartilage, joint lining, and muscle plausibly mediate the effect. Both arms of the large randomised programme tested this: estrogen plus progestogen relieved existing joint pain and prevented new musculoskeletal symptoms, and estrogen-only therapy produced a modest but sustained reduction in joint pain frequency. Joint swelling moved slightly the other way with estrogen-only therapy, so the benefit is specific to pain rather than to all joint symptoms.

Magnitude: relief of joint pain or stiffness reported by 47.1% on estrogen plus progestogen versus 38.4% on placebo at one year (OR 1.43, 95% CI 1.24 to 1.64), per the Women’s Health Initiative symptom analysis; with estrogen-only therapy joint pain frequency fell from 79.2% to 76.3% at one year and remained lower through year three, while joint swelling rose from 39.7% to 42.1%, per the estrogen-alone joint symptom analysis.

Low 🟩

Reduced Coronary Heart Disease Risk With Early Initiation ⚠️ Conflicted

Estrogen improves endothelial function and slows plaque progression in healthy arteries. An open-label randomised trial of estradiol-based therapy and one imaging trial found benefit; the large primary-prevention trial of estrogen plus progestogen found none, and a second imaging trial found none. Net reading: benefit only with early initiation.

Magnitude: composite of death, heart failure, or myocardial infarction reduced from 33 to 16 events over ten years (HR 0.48, 95% CI 0.26 to 0.87) in the Danish randomised trial of estradiol-based therapy; the stratified analysis of the large primary-prevention trial gives HR 0.76 within ten years of menopause versus 1.28 at twenty years or more; the trial of early versus late estradiol and carotid wall thickness found slowing only with early initiation, while the trial of arterial imaging outcomes in recently menopausal women found none.

Lower Death From Any Cause With Early Initiation ⚠️ Conflicted

Pooled randomised evidence shows no overall effect on death, but five trials starting before age 60 or within ten years of menopause showed a reduction. The signal is a subgroup finding spanning both estrogen-only and combined regimens. Net reading: neutral overall, possibly favourable when started near menopause.

Magnitude: RR 0.99 (95% CI 0.94 to 1.05) across 43 trials, but RR 0.70 (95% CI 0.52 to 0.95) in five early-initiation trials, per the mortality meta-analysis; 18-year follow-up of the largest trial found no mortality difference.

Preserved Cognitive Function With Early Initiation ⚠️ Conflicted

Estrogen supports hippocampal synaptic density and cerebral glucose metabolism, but human results split by age at initiation. Pooled analyses of trials and cohorts find no consistent benefit, and none for dementia prevention in either direction. Evidence covers both estrogen-only and combined regimens. Net reading: no reliable cognitive benefit is established.

Magnitude: no significant association with mild cognitive impairment or dementia across ten studies and 1,016,055 participants (subgroups by timing, type, and duration all null), per the dementia meta-analysis; the cognition meta-analysis of 34 trials found no overall effect but better verbal memory with estrogen started in midlife (standardised mean difference 0.394, 95% CI 0.014 to 0.774).

Reduced Colorectal Cancer Incidence ⚠️ Conflicted

Estrogen receptor beta signalling in colonic epithelium plausibly restrains tumour growth, and the estrogen-progestogen arm showed 44% fewer colorectal cancers during treatment. Over 24 years the difference disappeared, and cancers found during treatment had more often reached the lymph nodes. Net reading: the early reduction did not last.

Magnitude: 43 versus 72 cancers during 5.6 years of treatment, but HR 0.95 (95% CI 0.79 to 1.15) at 24 years, with numerically more colorectal deaths on therapy, per the long-term colorectal analysis.

Speculative 🟨

Slower Epigenetic Ageing

Methylation-clock estimates of biological age rise faster across the menopause transition and appear lower in users of estrogen-only and combined therapy. Epigenetic clocks are unvalidated surrogates; the basis is observational and mechanistic only.

Benefit-Modifying Factors

  • Baseline vasomotor symptom burden: The sleep, mood, and quality-of-life benefits are largest in women with moderate-to-severe hot flushes and essentially absent in women without them. Symptom burden is the single strongest predictor of whether systemic therapy delivers a felt benefit.

  • Time since final menstrual period: Coronary, mortality, and cognitive signals are favourable within ten years of menopause or before age 60, and neutral-to-adverse beyond. This window is the dominant modifier of every systemic benefit except bone and genitourinary outcomes.

  • Baseline bone mineral density: Fracture benefit scales with baseline risk. A woman with a hip T-score (bone density relative to a young-adult average) below −2.0 or a prior fragility fracture gains several times the absolute protection of a woman with normal density.

  • Premature ovarian insufficiency and early menopause: Women whose ovaries fail before 40 (premature ovarian insufficiency) or before 45 carry elevated cardiovascular, bone, and cognitive risk from earlier exposure loss, and derive correspondingly larger benefit from replacement until the average age of natural menopause.

  • Baseline metabolic status: Insulin resistance, central adiposity, and pre-diabetes at baseline amplify the diabetes-incidence benefit, and low baseline HDL cholesterol (the lipoprotein that removes cholesterol from tissue) predicts a larger favourable lipid shift with oral estradiol.

  • Genetic polymorphisms: ESR1 variants (the gene encoding estrogen receptor alpha) modify bone density response. CYP3A4 and CYP1A2 variants (liver enzymes that clear estradiol) alter systemic exposure from oral dosing. APOE4 carriers (a cholesterol-transport gene variant raising Alzheimer’s risk) may show a distinct cognitive response.

  • Pre-existing health conditions: Established atherosclerosis blunts or reverses the vascular benefit. Untreated hypothyroidism and uncontrolled hypertension mask symptom improvement. Prior hysterectomy (surgical removal of the uterus) removes the need for a progestogen and therefore removes the progestogen-linked breast cancer penalty from the benefit-risk calculation.

  • Age at the older end of the target range: Women beyond 65 retain the genitourinary and fracture benefits, which persist at any age, but the coronary, cognitive, and mortality signals invert. Low-dose vaginal therapy keeps its full benefit indefinitely.

  • Sex: This intervention is used in women; all benefit evidence above is female-only. Estrogen given to men, as in prostate cancer androgen deprivation, produces a different and largely unfavourable profile, so none of these findings transfer across sexes.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Venous Thromboembolism With Oral Routes

Venous thromboembolism is a clot in a deep vein or the lungs. Oral estradiol and oral conjugated estrogens pass through the liver first and raise procoagulant factors while lowering natural anticoagulants; transdermal estradiol does not, because it enters the circulation directly. Risk is highest in the first year and compounds with obesity, immobility, and inherited thrombophilia (a clotting tendency). Evidence covers both the estrogen-progestogen and estrogen-only arms of the large randomised programme plus a meta-analysis of observational studies separating route.

Magnitude: RR 2.03 (95% CI 1.55 to 6.64) for estrogen plus progestogen and RR 1.32 (95% CI 1.00 to 1.74) for estrogen-only therapy, both oral, per the Cochrane review; the route-stratified meta-analysis gives OR 2.5 (95% CI 1.9 to 3.4) for oral versus 1.2 (95% CI 0.9 to 1.7) for transdermal.

Ischaemic Stroke

Stroke risk rises with both regimens in the randomised data, and the mechanism — raised clotting factors and blood pressure from hepatic first-pass exposure — again points at the oral route and the dose. Absolute excess is small in women in their fifties and rises steeply with age, so the harm is concentrated in exactly the group least likely to be starting therapy for symptoms. Observational data separating route suggest low-dose transdermal estradiol carries no measurable excess.

Magnitude: RR 1.39 (95% CI 1.09 to 2.09) for estrogen plus progestogen and RR 1.33 (95% CI 1.06 to 1.67) for estrogen-only therapy, per the Cochrane review; the route-stratified case-control study gives rate ratio 1.28 (95% CI 1.15 to 1.42 — a rate ratio compares how often an event occurs per unit of time between groups) for oral therapy, 0.81 (95% CI 0.62 to 1.05) for low-dose estrogen patches, and 1.89 (95% CI 1.15 to 3.11) for high-dose patches.

Breast Cancer With Estrogen-Progestogen Regimens

The breast cancer signal is specific to adding a progestogen. Combined therapy increases incidence after roughly three to five years of use, plausibly by driving proliferation of existing occult lesions rather than initiating new ones. Estrogen-only therapy shows no increase in the randomised data and a reduction in long-term follow-up of the hysterectomised arm. Observational work suggests micronized progesterone and dydrogesterone carry less risk than synthetic progestins, though no randomised trial has tested that directly.

Magnitude: RR 1.27 (95% CI 1.03 to 1.56) for estrogen plus progestogen versus RR 0.79 (95% CI 0.61 to 1.01) for estrogen-only therapy, per the Cochrane review; the 2026 meta-analysis gives OR 1.44 for combined and 1.00 for estrogen-only therapy, and the E3N cohort separates progestogen types.

Endometrial Hyperplasia and Cancer With Unopposed Estrogen

Estrogen without a progestogen drives continuous proliferation of the endometrium, producing hyperplasia (overgrowth of the lining) and, with time, carcinoma. This is the single most reliably established harm in the field and the reason combined regimens exist. Adequate progestogen dosing — continuous, or cyclical for at least 12 days per month — abolishes the excess. A levonorgestrel-releasing intrauterine system delivers equivalent protection locally. The risk applies only to women who retain a uterus.

Magnitude: unopposed estrogen raised endometrial hyperplasia at every dose studied and at durations of one to three years, while continuous low-dose estrogen combined with at least 1 mg norethisterone acetate was no different from placebo at two years (OR 0.04, 95% CI 0 to 2.8), per the Cochrane review of endometrial hyperplasia risk.

Gallbladder Disease Requiring Surgery

Oral estrogen increases biliary cholesterol saturation and slows gallbladder emptying, promoting gallstone formation. The excess is larger for estrogen-only than combined therapy and is one of the few harms more common with the estrogen-only regimen. It is a nuisance-to-moderate harm rather than a life-threatening one, but it drives real surgical volume — and it is route-dependent, so transdermal delivery is the obvious lever.

Magnitude: RR 1.64 (95% CI 1.30 to 2.06) for estrogen plus progestogen and RR 1.78 (95% CI 1.42 to 2.24) for estrogen-only therapy, both oral, per the Cochrane review; the umbrella review confirms the association in pooled randomised data.

Vaginal Bleeding and Breast Tenderness

The commonest reasons women stop therapy are not the serious harms but the nuisance ones. Unscheduled bleeding is near-universal in the first months of continuous combined therapy and mandates investigation if it persists beyond six months, because it cannot be distinguished clinically from endometrial pathology. Breast tenderness, fluid retention, joint pain, and headache cluster in the first weeks and usually settle or respond to dose reduction. Both regimens are affected.

Magnitude: vaginal bleeding in 54.1% of women on estrogen plus progestogen versus 5.2% on placebo at six months, per the long-term Women’s Health Initiative report; any adverse event OR 1.41 (95% CI 1.00 to 1.99) versus placebo, commonly breast tenderness, oedema, and joint pain, per the Cochrane meta-analysis.

Medium 🟥 🟥

Dementia When Started After Age 65

In women aged 65 and over, estrogen plus progestogen doubled probable dementia over four years. The proposed mechanism is that estrogen acts unfavourably on an already-damaged cerebral vasculature, consistent with the timing account. The estrogen-only arm showed a smaller, non-significant increase. The pooled dementia meta-analysis across all ages finds no association in either direction, so this harm is specific to late initiation rather than to hormone therapy generally.

Magnitude: HR 2.05 (95% CI 1.21 to 3.48) for probable dementia in women aged 65 and over on estrogen plus progestogen, an absolute 45 versus 22 cases per 10,000 person-years, per the Women’s Health Initiative Memory Study.

Ovarian Cancer

Current use of either regimen is associated with a modest increase in ovarian cancer, concentrated in serous and endometrioid subtypes (the two commonest tissue types of ovarian tumour), and declining after cessation. The evidence is an individual-participant meta-analysis of 52 epidemiological studies rather than randomised data, so residual confounding cannot be excluded — but the dose-response with duration and the decline after stopping both argue for causality. The absolute excess is small.

Magnitude: RR 1.43 (95% CI 1.31 to 1.56) among current users even with fewer than five years of use, equating to roughly one extra ovarian cancer per 1,000 women using therapy for five years from around age 50 and one extra ovarian cancer death per 1,700, per the individual-participant meta-analysis.

Urinary Incontinence With Systemic Therapy

Systemic estrogen worsens urinary incontinence, which is the opposite of the effect of low-dose vaginal estrogen — a genuine route paradox rather than a contradiction. Both systemic arms of the large randomised programme increased new-onset stress and mixed incontinence and worsened existing symptoms. Women troubled by urinary symptoms alone are therefore better served by the vaginal route. Evidence covers both estrogen-only and estrogen-progestogen regimens.

Magnitude: new stress incontinence RR 1.87 (95% CI 1.61 to 2.18) for estrogen plus progestogen and RR 2.15 (95% CI 1.77 to 2.62) for estrogen-only therapy at one year, with frequency worsening in already-symptomatic women in both arms (RR 1.38 and 1.47), per the Women’s Health Initiative incontinence analysis.

Raised Blood Pressure With Oral Estrogen

Oral estrogen increases hepatic angiotensinogen synthesis, activating the renin-angiotensin-aldosterone system (the hormone cascade controlling blood pressure and fluid balance) and modestly raising blood pressure. Transdermal delivery avoids the first-pass effect and shows no such association. The absolute rise is a few millimetres of mercury on average but is concentrated in susceptible women, and it compounds the stroke signal above.

Magnitude: oral estrogen-only therapy carried a 14% higher risk of incident hypertension than transdermal (HR 1.14, 95% CI 1.08 to 1.20) and 19% higher than vaginal estrogen (HR 1.19, 95% CI 1.13 to 1.25) across 112,240 women, with risk rising with dose and duration, per the population-based cohort study of route and hypertension risk.

Low 🟥

Coronary Events When Started Long After Menopause ⚠️ Conflicted

In women starting therapy more than ten years past menopause, coronary events trended upward early in treatment, plausibly through plaque destabilisation in already-diseased arteries. The pooled randomised estimate does not reach significance, and the estrogen-only arm shows no signal. Net reading: an age-dependent early hazard, not a general one.

Magnitude: RR 1.17 (95% CI 0.95 to 1.44) for coronary events with estrogen plus progestogen and RR 0.94 (95% CI 0.78 to 1.13) for estrogen-only therapy, per the Cochrane review; the stratified analysis of the same programme gives HR 1.28 in women twenty or more years past menopause.

Lung Cancer Mortality With Estrogen-Progestogen ⚠️ Conflicted

Pooled randomised data associate combined therapy with increased death from lung cancer without increasing incidence, suggesting an effect on tumour behaviour rather than initiation. The current Cochrane analysis finds no incidence difference for either regimen. Net reading: a mortality signal without an incidence signal, unresolved.

Magnitude: lung cancer mortality is raised with estrogen plus progestogen in pooled randomised data and not with estrogen-only therapy, but the umbrella review reports the association without an outcome figure; lung cancer incidence is unchanged at RR 1.06 (95% CI 0.77 to 1.46) in the Cochrane review.

Meningioma

Progestogen exposure, particularly high-dose or prolonged synthetic progestin use, is associated with meningioma — a usually benign tumour of the membranes covering the brain. The evidence is observational only and the absolute risk is very low, but tumours can regress on withdrawal.

Magnitude: increased meningioma risk in pooled observational data, with no randomised estimate available and no reliable absolute figure across regimens, per the umbrella review.

Speculative 🟨

Risk-Modifying Factors

  • Route of administration: The dominant modifier. Transdermal estradiol bypasses hepatic first-pass metabolism and largely removes the venous thromboembolism, stroke, gallbladder, and blood-pressure excesses that attach to oral dosing.

  • Progestogen choice: Synthetic progestins carry the breast cancer signal; observational data associate micronized progesterone and dydrogesterone with lower risk. A levonorgestrel intrauterine system confines exposure mostly to the endometrium.

  • Inherited thrombophilia (a clotting tendency): Factor V Leiden (a clotting factor variant resistant to inactivation) and prothrombin G20210A (raising the clot-forming protein prothrombin) multiply oral estrogen’s clot risk severalfold. CYP3A4 and CYP1A2 variants alter estradiol clearance and systemic exposure.

  • Baseline biomarkers: Elevated triglycerides above 300 mg/dL predict pancreatitis with oral estrogen. Raised ALT (a liver enzyme) or abnormal clotting screens flag hepatic and thrombotic risk. Mammographic density predicts detection difficulty.

  • Pre-existing conditions: Established coronary disease, prior stroke, active liver disease, gallstones, migraine with aura, hormone-receptor-positive breast cancer, and unexplained vaginal bleeding each shift the balance substantially, several to the point of exclusion.

  • Age and time since menopause: Every serious harm — stroke, clots, dementia, coronary events — rises with age at initiation. Beyond 60, or beyond ten years past the final period, absolute harm climbs while the coronary and cognitive signals invert.

  • Body mass index and smoking: Obesity roughly doubles the clot risk added by oral estrogen; smoking compounds stroke and clot risk and is the strongest modifiable amplifier of both.

  • Sex: All risk estimates above derive from female populations. Estrogen exposure in men, as in androgen deprivation therapy, carries a distinct cardiovascular and thromboembolic profile that does not transfer to this intervention.

Key Interactions & Contraindications

  • CYP3A4 inducers — prescription (rifampicin, carbamazepine, phenytoin, phenobarbital, efavirenz): Caution; accelerate estradiol and progesterone clearance, causing loss of symptom control and, with unopposed estrogen exposure, inadequate endometrial protection. Mitigation: switch to transdermal delivery or raise the dose with symptom monitoring.

  • CYP3A4 inhibitors — prescription (ketoconazole, itraconazole, ritonavir, clarithromycin, diltiazem): Monitor; raise estradiol and progesterone exposure, increasing breast tenderness, bleeding, and thrombotic risk. Mitigation: reduce estrogen dose by one increment and reassess after four weeks.

  • Levothyroxine (thyroid hormone replacement): Monitor; oral estrogen raises thyroxine-binding globulin, lowering free thyroid hormone and increasing dose requirement. Mitigation: check TSH (thyroid stimulating hormone) 6–8 weeks after starting or changing oral estrogen.

  • Lamotrigine (anticonvulsant): Caution; oral estrogen induces lamotrigine glucuronidation and can halve its concentration, risking seizure breakthrough. Mitigation: measure lamotrigine levels before and 4 weeks after starting, and prefer transdermal estradiol.

  • Anticoagulants (warfarin, apixaban, rivaroxaban): Caution; oral estrogen’s procoagulant shift partially opposes anticoagulation and complicates control. Mitigation: use transdermal estradiol and monitor INR (a clotting time measure) more frequently after any change.

  • Tamoxifen and aromatase inhibitors (estrogen-blocking cancer drugs — anastrozole, letrozole, exemestane): Absolute contraindication in combination; systemic estrogen directly opposes the therapeutic intent of endocrine cancer treatment. Mitigation: none for systemic therapy; low-dose vaginal estrogen may be considered only with the treating oncologist.

  • Corticosteroids (prednisolone, dexamethasone) and ciclosporin — prescription immunosuppressants: Monitor; oral estrogen reduces their hepatic clearance, raising exposure and toxicity. Mitigation: monitor ciclosporin levels and watch for corticosteroid excess; transdermal delivery avoids the interaction.

  • Over-the-counter acetaminophen (paracetamol): Monitor; competes for sulfation and glucuronidation, transiently raising estradiol concentrations with regular high-dose use. Mitigation: no routine change required; consider it if estrogenic side effects appear alongside daily analgesic use.

  • Over-the-counter orlistat (alli): Caution; reduces intestinal absorption of fat-soluble compounds and can lower oral estradiol and progesterone exposure. Mitigation: separate dosing by at least two hours, or use transdermal estradiol and vaginal progesterone.

  • St John’s wort (supplement): Caution; a potent CYP3A4 inducer that markedly lowers estradiol and progesterone levels, causing breakthrough bleeding and symptom return. Mitigation: avoid concurrent use, or switch antidepressant strategy.

  • Phytoestrogen supplements (soy isoflavones, red clover, black cohosh, Pueraria mirifica): Monitor; additive estrogen-receptor activity of uncertain magnitude that can confound dose titration and symptom assessment. Mitigation: stop phytoestrogens before starting therapy and reintroduce only after the dose is stable.

  • DHEA (dehydroepiandrosterone, an adrenal precursor supplement): Monitor; converts peripherally to both estradiol and testosterone, adding uncontrolled hormone exposure on top of a titrated regimen. Mitigation: measure total testosterone and estradiol if both are used, and treat DHEA as part of the total dose.

  • Combined oral contraceptives (ethinylestradiol–levonorgestrel, ethinylestradiol–drospirenone) and other exogenous estrogens: Absolute contraindication in combination; duplicative estrogen exposure with multiplied thrombotic risk. Mitigation: transition directly from contraception to hormone therapy rather than overlapping.

Populations who should avoid Female HRT:

  • Current, past, or suspected hormone-receptor-positive breast cancer, at any interval since treatment
  • Active venous thromboembolism, or an event within the past 3–6 months, or high-risk thrombophilia such as homozygous Factor V Leiden or antithrombin deficiency
  • Myocardial infarction, unstable angina, or ischaemic stroke within the past 12 months, or established symptomatic coronary artery disease
  • Active liver disease with ALT above three times the upper limit of normal, or cirrhosis of Child-Pugh Class B or C (a severity grading of liver failure)
  • Untreated endometrial hyperplasia, active endometrial cancer, or unexplained postmenopausal vaginal bleeding not yet investigated
  • Known or suspected pregnancy
  • Fasting triglycerides above 500 mg/dL when oral estrogen is proposed, because of pancreatitis risk
  • Systemic therapy initiated after age 60, or more than 10 years past the final menstrual period, in a woman without vasomotor symptoms

Risk Mitigation Strategies

  • Transdermal estradiol as the default route: Patches, gels, or sprays bypass hepatic first-pass metabolism and largely remove the excess clot, stroke, gallbladder, and blood-pressure risk that attaches to oral dosing. Typical starting dose 25–50 µg daily by patch.

  • Micronized progesterone or dydrogesterone rather than synthetic progestins: Mitigates the progestogen-linked breast cancer signal. Standard protective dosing is 100 mg nightly continuously, or 200 mg nightly for 12–14 days per month on a cyclical regimen.

  • Adequate, never-omitted endometrial protection: Any woman retaining a uterus takes a progestogen with systemic estrogen, or uses a levonorgestrel intrauterine system, to prevent endometrial hyperplasia and carcinoma. Estrogen-only systemic therapy is reserved for women after hysterectomy.

  • Lowest effective dose with upward titration: Protocols open at 25 µg transdermal estradiol or 0.5 mg oral estradiol, reassess symptoms at 6–8 weeks, and step up only where control is incomplete. This limits breast tenderness, bleeding, and dose-dependent stroke risk.

  • Initiation within the ten-year window: Initiating within ten years of the final menstrual period, or before age 60, is the single decision that most reduces the coronary, stroke, and dementia hazards seen with late initiation.

  • Investigation of persistent unscheduled bleeding: Any bleeding continuing beyond six months of continuous combined therapy, or any new bleeding after amenorrhoea (absence of periods), warrants transvaginal ultrasound and endometrial sampling to exclude hyperplasia or carcinoma.

  • Vaginal rather than systemic estrogen for urinary symptoms: Systemic therapy worsens stress and mixed incontinence while low-dose vaginal estrogen improves it, so isolated genitourinary complaints are addressed locally at 10 µg estradiol twice weekly after loading.

  • Thrombophilia screening where family history warrants: A first-degree relative with unprovoked venous thromboembolism before 50 justifies testing for Factor V Leiden and prothrombin G20210A before oral estrogen, and transdermal dosing regardless of result.

  • Mammographic surveillance and control of modifiable amplifiers: Two-yearly mammography, smoking cessation, and body mass index below 30 address the breast cancer detection problem and the two strongest multipliers of stroke and clot risk.

Therapeutic Protocol

  • Standard contemporary regimen: Transdermal estradiol 25–100 µg daily by patch, or 0.75–1.5 mg daily by gel, plus oral micronized progesterone 100 mg nightly continuously in women with a uterus. This is the regimen most menopause specialists now start with.

  • Conventional oral alternative: Oral estradiol 1–2 mg daily, or conjugated equine estrogens 0.3–0.625 mg daily, with medroxyprogesterone acetate 2.5 mg daily. Cheaper and long-studied, but carries the hepatic first-pass risks described above.

  • Cyclical versus continuous progestogen: Perimenopausal women who still bleed usually take micronized progesterone 200 mg nightly for 12–14 days monthly, producing a withdrawal bleed; postmenopausal women take 100 mg nightly continuously for amenorrhoea (no bleeding).

  • Competing approach — body-identical restoration: Restorative and functional medicine practitioners, including those featured by Life Extension (a supplement retailer selling the products this position endorses) and Chris Kresser, titrate estradiol and progesterone to premenopausal serum concentrations.

  • Competing approach — symptom-limited minimum dosing: The Menopause Society and the British Menopause Society, both of which receive substantial industry sponsorship for meetings and education, advocate the lowest dose controlling symptoms, for the shortest period meeting the woman’s goals.

  • Local therapy as a standalone option: Vaginal estradiol 10 µg tablet or estriol 0.5 mg cream, nightly for two weeks then twice weekly indefinitely. Systemic absorption is negligible, no progestogen is required, and it can continue lifelong.

  • Testosterone as an optional third component: Transdermal testosterone titrated to a total testosterone in the upper premenopausal range, popularised in this context by Susan Davis’s group at Monash University and by Rachel Rubin in clinical practice.

  • Best time of day: Estradiol patches are changed on a fixed twice-weekly or weekly schedule; gels are applied each morning. Micronized progesterone is taken at bedtime because its sedative metabolite aids sleep and blunts daytime drowsiness.

  • Half-life and dosing frequency: Oral estradiol’s half-life of 12–14 hours supports once-daily dosing; transdermal patches deliver steady concentrations over 3.5 or 7 days. Oral micronized progesterone’s 5-hour half-life makes single nightly dosing standard.

  • Single versus split dosing: Estradiol gel above 1.5 mg daily is often split morning and evening to smooth peaks and reduce breast tenderness. Progesterone is never split, since night-time dosing is the point.

  • Genetic polymorphisms influencing dose: CYP3A4 and CYP1A2 poor metabolisers reach higher estradiol levels from oral dosing and often need lower starting doses. Factor V Leiden carriers are directed to transdermal delivery irrespective of dose.

  • Sex-based differences: All dosing above is female-specific and derived from female trials. Male estrogen regimens serve different indications at different doses and have no bearing on the protocols here.

  • Age-related considerations: Women starting after 60 begin at half the standard dose — 25 µg transdermal estradiol — because absolute stroke and clot risk rises with age. Women over 70 initiating systemic therapy are uncommon outside symptom emergencies.

  • Baseline biomarkers influencing response: A pretreatment estradiol below 20 pg/mL and FSH (follicle stimulating hormone, the pituitary signal that rises when ovaries fail) above 30 mIU/L confirm the menopausal state and predict a fuller symptom response.

  • Pre-existing conditions influencing response: Untreated hypothyroidism, iron deficiency, and obstructive sleep apnoea mimic menopausal symptoms and blunt apparent response. Migraine with aura and hypertriglyceridaemia (raised blood fats) both direct the choice toward transdermal delivery.

Discontinuation & Cycling

  • Duration framing: No fixed stopping date is evidence-based. Systemic therapy is typically continued while benefits outweigh risks, reassessed annually; vaginal estrogen is genuinely indefinite because genitourinary symptoms return without it.

  • Stopping the components separately: Estrogen and progestogen are stopped together. Continuing a progestogen alone serves no purpose, and continuing estrogen alone in a woman with a uterus reinstates endometrial cancer risk immediately.

  • Withdrawal effects: Hot flushes, night sweats, and sleep disruption return in roughly half of women on stopping, sometimes within days, and can be as severe as before treatment. Mood symptoms may also recur.

  • Tapering protocol: Gradual reduction over 3–6 months — stepping transdermal estradiol from 50 to 37.5 to 25 µg, then alternate days — reduces rebound vasomotor symptoms compared with abrupt cessation, though trial evidence for tapering is limited.

  • Bone loss on cessation: Fracture protection is not retained. Bone mineral density falls at the accelerated early-menopause rate once therapy stops, so a repeat bone density scan 1–2 years after discontinuation is standard practice.

  • Cycling is not used for efficacy: Tachyphylaxis (loss of response with repeated dosing) does not develop, so no drug holiday preserves response. The only cycling here is the monthly progestogen phase of a sequential regimen, serving endometrial protection.

Sourcing and Quality

  • Regulated pharmaceutical products preferred: Estradiol patches, gels, sprays, and oral micronized progesterone are pharmacopoeial products with verified content and release characteristics. This is the sourcing default for every component of the regimen.

  • Compounded bioidentical preparations: Regulators in the United States and United Kingdom advise against custom-compounded creams and pellets where an approved product exists, citing the absence of premarket review and documented deviations from labelled potency.

  • Estradiol formulations: Patches (Climara, Vivelle-Dot, Estradot) differ in adhesive and release profile; gels (EstroGel, Divigel) in application area. Switching brands at equal nominal dose can change absorbed exposure noticeably.

  • Progesterone formulations: Oral micronized progesterone (Prometrium, Utrogestan) is peanut-oil based in some markets, which matters for allergy. Dydrogesterone is a separate molecule, not interchangeable milligram for milligram.

  • Testosterone sourcing: No female-dose testosterone product is licensed in most markets, so male transdermal gel is dispensed at roughly one-tenth dose or compounded. This is the one component where compounding is often unavoidable.

  • Third-party testing: Not applicable in the usual supplement sense, since these are prescription pharmaceuticals subject to regulatory batch release. Where compounding is unavoidable, a certificate of analysis with independent potency verification is the equivalent safeguard.

  • Reputable compounding pharmacies: Where compounding is necessary, pharmacies accredited by the Pharmacy Compounding Accreditation Board in the United States, or registered specials manufacturers in the United Kingdom, provide documented potency and sterility standards.

Practical Considerations

  • Time to effect: Hot flushes improve within 2–4 weeks and plateau by 12 weeks. Sleep and mood follow the same curve. Genitourinary symptoms need 8–12 weeks of vaginal estrogen. Bone density changes take 12 months to measure.

  • Common pitfall — stopping too early: Breast tenderness, bloating, and unscheduled bleeding peak in the first 6–12 weeks and then settle. Many women discontinue during this window and conclude the therapy failed.

  • Common pitfall — underdosing the progestogen: Fewer than 12 days of cyclical progestogen, or skipped doses on a continuous regimen, leaves the endometrium inadequately opposed while the woman believes herself protected.

  • Common pitfall — treating urinary symptoms systemically: Systemic estrogen worsens stress incontinence while vaginal estrogen improves it, so the wrong route makes the complaint worse.

  • Regulatory status: Systemic estradiol and progesterone are approved for vasomotor symptoms, genitourinary symptoms, and osteoporosis prevention. Use for cardiovascular, cognitive, or longevity indications is off-label. Female testosterone use is off-label in most markets.

  • Structural incentive in guideline formation: Generic estradiol and progesterone cost roughly $10–30 monthly, while branded non-hormonal alternatives for hot flushes cost $500–650 monthly. Insurers and national health systems therefore have a systematic financial incentive favouring hormone therapy over its newer competitors.

  • Conflicts of interest across cited parties: The Menopause Society, the British Menopause Society, and the International Menopause Society all derive meeting and education revenue from hormone manufacturers, and many menopause specialists hold advisory relationships. Compounding pharmacies and menopause telehealth companies carry the mirror-image incentive.

  • Cost and accessibility: Generic transdermal estradiol and oral micronized progesterone are inexpensive and widely stocked. Access is limited more by prescriber confidence, which collapsed after 2002 and has recovered unevenly, than by price.

Interaction with Foundational Habits

  • Sleep: Direct and potentiating. Estrogen removes night sweats that fragment sleep, and oral micronized progesterone taken at bedtime is independently sedating through its GABA-A-active metabolite allopregnanolone. Taking progesterone in the morning wastes this effect and causes daytime drowsiness. Evidence: the sleep-quality meta-analysis.

  • Nutrition: Indirect. No food restriction is required, but oral estradiol’s first-pass metabolism raises triglycerides, so a high-refined-carbohydrate intake compounds that shift. Adequate calcium of 1,000–1,200 mg daily and vitamin D of 800–2,000 IU daily are needed for the fracture benefit to be fully realised. Grapefruit juice inhibits CYP3A4 and raises estradiol exposure.

  • Exercise: Potentiating, not blunting. Resistance and impact loading act on bone through mechanical strain while estrogen acts on osteoclasts, so the effects are complementary. No timing relative to dosing is required. Hormone therapy does not blunt hypertrophy: a meta-analysis of nine randomised trials found no effect on muscle strength.

  • Stress management: Indirect. Estrogen dampens hypothalamic-pituitary-adrenal axis reactivity (the body’s core stress-hormone loop), and the depression-prevention trial found benefit largest in women with recent stressful life events. Chronic psychological stress worsens vasomotor symptoms independently, so stress reduction and hormone therapy address the same endpoint by separate routes.

Monitoring Protocol & Defining Success

Before starting, a baseline assessment establishes eligibility and a reference point: blood pressure, height and weight, a fasting lipid and glucose panel, liver enzymes, thyroid function, and confirmation of menopausal status by estradiol and follicle stimulating hormone where the picture is ambiguous. Mammography and cervical screening are brought up to date, and a bone density scan is obtained where fracture risk is elevated. A written symptom baseline matters as much as the bloodwork.

Ongoing monitoring follows a defined cadence: a symptom and side-effect review at 6–8 weeks, a full review with blood pressure and weight at 3 months, then at 6 months, and annually thereafter. Lipids, glucose, and liver enzymes are repeated annually. Bone density is repeated every 2 years where it guided the decision, and mammography continues on the standard 2-yearly interval.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Estradiol (E2) 50–100 pg/mL on transdermal therapy Confirms absorption and guides titration Conventional postmenopausal reference is below 30 pg/mL; not useful for oral dosing or for vaginal-only therapy. Draw mid-patch-interval
FSH No established on-treatment target; track symptom response and estradiol instead Confirms menopausal status before starting FSH means follicle stimulating hormone, the pituitary signal that rises when the ovaries fail; above 30 mIU/L pretreatment supports the diagnosis. Suppression on therapy is inconsistent
Blood pressure Below 120/80 mmHg Oral estrogen raises it through the renin-angiotensin system Measure seated after 5 minutes’ rest; a sustained rise is a prompt to switch from oral to transdermal delivery
ApoB Below 80 mg/dL Best single marker of atherogenic particle burden ApoB means apolipoprotein B, one molecule per artery-entering lipid particle. Conventional laboratories flag only values above roughly 130 mg/dL. Fasting not required. Pair with lipoprotein(a) once in a lifetime
Triglycerides Below 100 mg/dL Oral estrogen raises them; above 500 mg/dL carries pancreatitis risk Conventional reference is below 150 mg/dL. Requires a 12-hour fast. A rise above 300 mg/dL on oral estrogen is an indication to move to transdermal
HbA1c 4.8–5.4% Tracks the glycaemic benefit and detects deterioration HbA1c means glycated haemoglobin, a 3-month average of blood glucose. Conventional reference calls anything below 5.7% normal. No fasting required; unreliable in anaemia
ALT Below 20 U/L Screens for hepatic injury and fatty liver before and during oral dosing ALT means alanine aminotransferase, a liver enzyme released when liver cells are damaged. Conventional upper limits run to about 33 U/L in women. Best paired with gamma-glutamyl transferase and a fasting lipid panel
TSH 0.5–2.5 mIU/L Oral estrogen raises thyroid hormone requirement TSH means thyroid stimulating hormone. Conventional reference extends to about 4.5 mIU/L. Recheck 6–8 weeks after starting or changing oral estrogen, before 9 am, and pair with free thyroxine
SHBG 30–90 nmol/L Rises sharply with oral estrogen, lowering free testosterone SHBG means sex hormone binding globulin, the protein that carries sex hormones in blood. Conventional postmenopausal reference runs roughly 18–144 nmol/L. A marked rise explains loss of libido on oral therapy
Total testosterone 20–70 ng/dL when testosterone is used Prevents supraphysiological dosing and androgenic side effects Draw in the morning before gel application, alongside SHBG so free testosterone can be calculated
25-hydroxyvitamin D 40–60 ng/mL Required for the fracture benefit to be realised Conventional sufficiency threshold is only 30 ng/mL. Pair with calcium and parathyroid hormone if bone loss continues
Bone mineral density (DXA T-score) Above −1.0 Objective measure of the skeletal benefit DXA means dual-energy X-ray absorptiometry, the standard bone density scan. Repeat every 2 years; same machine each time for comparability
Endometrial thickness (transvaginal ultrasound) Below 4 mm without therapy; below 8 mm on sequential therapy Detects inadequately opposed estrogen effect Not a routine screening test; performed when unscheduled bleeding persists beyond 6 months or recurs after amenorrhoea

Qualitative markers that define success are tracked alongside the laboratory values:

  • Frequency and severity of hot flushes and night sweats, scored weekly for the first three months
  • Sleep continuity — number of night-time awakenings and subjective restedness on waking
  • Mood stability, irritability, and anxiety, ideally against a written pretreatment baseline
  • Cognitive clarity and word-finding, which many women report as the most disabling symptom
  • Vaginal comfort, absence of pain during intercourse, and urinary urgency or frequency
  • Sexual desire and satisfaction, especially where testosterone has been added
  • Joint pain and morning stiffness, which frequently improve and are rarely attributed to the therapy
  • Energy and exercise tolerance, and whether training capacity has returned toward premenopausal levels

Emerging Research

  • Hormone therapy and Alzheimer’s biomarkers: The HARALD trial (NCT04312399, 600 women aged 40–65, recruiting at Ghent University Hospital) compares oral and transdermal regimens against no therapy, measuring plasma amyloid, total tau, and neurofilament light, with APOE genotyping. Primary completion is estimated for December 2027.

  • Bone remodelling with contemporary regimens: COMPASS (NCT07254429, Phase 2, 192 women, recruiting in Copenhagen) measures change in bone remodelling markers at eight weeks, comparing a gonadotropin-releasing hormone analog against placebo with transdermal estradiol and transdermal testosterone as active comparator arms.

  • Estradiol and testosterone implants: ESTIME (NCT06343870, Phase 3, 140 women, University of São Paulo) evaluates a subdermal testosterone implant against a placebo pellet on pharmacokinetic, hormonal, metabolic, and thromboembolic endpoints — a design that could weaken the case for implants, which are widely used but poorly evidenced.

  • Metabolic interaction with GLP-1 agonists: A Swiss trial (NCT06715514, 96 postmenopausal women with type 2 diabetes) measures HbA1c change with hormone therapy alongside GLP-1 receptor agonists (a diabetes and weight-loss drug class including semaglutide), testing whether the two metabolic effects are additive.

  • Registry-scale mortality evidence: Mikkelsen et al., 2026 analysed over 800,000 Danish women and found no excess mortality, with 27–34% lower mortality in those who had ovaries removed between 45 and 54. Sibling comparisons reduced but did not eliminate healthy-user confounding.

  • Regimen-specific breast cancer risk: Wu et al., 2026 found marked geographical heterogeneity in the breast cancer association, unexplained by regimen. Whether this reflects differing progestogen formulations by market or residual confounding is the open question, and either answer would shift risk estimates substantially.

  • Timing hypothesis, still unresolved: No adequately powered trial has tested hard cardiovascular endpoints in women starting within ten years of menopause. Until one exists, the claim rests on subgroup analyses, Schierbeck et al., 2012, and one of two imaging trials, Hodis et al., 2016.

Conclusion

Female HRT replaces the estrogen, and usually the progesterone, that the ovaries stop making at menopause. The strongest evidence, repeated across many well-controlled trials, is that it relieves hot flushes and night sweats, restores tissue in the genital and urinary tract, reduces broken bones, lowers the chance of developing adult-onset diabetes, and improves sleep in women whose sleep is broken by night sweats. Added testosterone improves sexual desire and satisfaction.

The harms are equally well established, and most of them track the route and the choice of second hormone. Oral estrogen raises the risk of clots and stroke; transdermal estrogen appears not to. Adding a laboratory-made progesterone substitute raises breast cancer risk; estrogen given alone to women without a uterus does not. Gallbladder surgery, unexpected bleeding, and breast tenderness are common enough to matter. Estrogen without a partner hormone thickens the lining of the uterus, which is why it is not given alone to women who still have one.

When therapy starts appears to change the arithmetic, though that evidence is weaker and openly contradictory: the effects on heart disease, on thinking, and on length of life point in different directions depending on age at the start. Much of the older evidence was paid for by the companies selling the hormones, and the professional bodies writing menopause guidance draw meeting income from the same industry — a conflict sitting on every side of this argument.

Top - Benefits - Risks - Protocol